ASAngela R. Subauste

Angela R. Subauste

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela R. Subauste has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study

    by Aditi Kumar, Chad Blackshear, Jose S. Subauste, Nazanene H. Esfandiari, Elif Arioglu Oral, Angela R. Subauste

    Context: Fatty liver disease is one of the most common forms of chronic liver disease. The renin-angiotensin-aldosterone system has been implicated in the pathogenesis of fatty liver. Objective: Determine the relationship between fatty liver and aldosterone in a large cohort study. Design: Community-based, observational cohort study of African Americans. Setting: The original Jackson Heart Study cohort enrolled African American participants from the Jackson, Mississippi, metropolitan area in Hinds, Madison, and Rankin Counties. Participants: Our study population consisted of 2507 Jackson Heart Study participants (1625 women and 882 men) who had liver attenuation measured per computed tomography scans, had aldosterone measurements, and were not taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or mineralocorticoid receptor antagonists. Intervention: There was no intervention. Main outcome measure: Liver attenuation on computed tomography scans. Results: Univariate regression analysis demonstrated a statistically significant correlation between aldosterone levels and liver attenuation. Each doubling of aldosterone was associated with 1.08 Hounsfield unit decrease (95% confidence interval, 1.47 to −0.69, P < 0.001). A multivariable model adjusted for body mass index, age, alcohol intake, and homeostatic model assessment of insulin resistance determined that the association was statistically significant only for women. Conclusion: Our data demonstrate a positive association between aldosterone levels and fatty liver in African American women.


  • Open Access

    Milestone Weight Loss Goals (Weight Normalization and Remission of Obesity) after Gastric Bypass Surgery: Long-Term Results from the University of Michigan

    by Corey J. Lager, Nazanene H. Esfandiari, Angela R. Subauste, Andrew T. Kraftson, Morton B. Brown, Ruth B. Cassidy, Darlene Bellers, Amy L. Lockwood, Oliver A. Varban, Elif A. Oral

    Background Rates of weight normalization and obesity remission after Roux-en-Y gastric bypass (GB) are unknown. This study evaluated weight loss, rates of achieving body mass index (BMI) 2, recidivism, and predictors of success following GB. Methods We retrospectively studied weight and BMI at baseline, 2 and 6 months, and annually at 1–7 years in 219 patients undergoing GB at the University of Michigan from January 2008 to November 2010. Results Follow-up was excellent for a population traditionally associated with high attrition rates with data availability of 157/219, 145/219, 144/219, 134/219, 123/219, 82/161, and 29/64 patients at 1–7 years, respectively. Mean baseline BMI was 47.0 kg/m2. Weight normalization (BMI 2) occurred in 2.3–6.8% of patients. More importantly, 47% of patients achieved remission of obesity (BMI 2) at some time point and 24% (52/219) at the last observed time point. BMI 2 was associated with a lower initial BMI and follow-up for more than 2 years. Conclusions Rates of weight normalization are low after GB; however, a large number of patients achieved BMI 2. While the percent total weight loss and excess weight loss are both quite high in the entire cohort and this is likely associated with significant health benefits, our results still underscore the need to address obesity with intensive clinical attention earlier in its course.


  • Open Access

    Diabetic muscle infarction: a systematic review

    by William B Horton, Jeremy S Taylor, Timothy J Ragland, Angela R Subauste

    Context Diabetic muscle infarction (DMI) is a rare complication associated with poorly controlled diabetes mellitus. Less than 200 cases have been reported in the literature since it was first described over 45 years ago. There is no clear ‘standard of care’ for managing these patients. Evidence acquisition PubMed searches were conducted for ‘diabetic muscle infarction’ and ‘diabetic myonecrosis’ from database inception through July 2014. All articles identified by these searches were reviewed in detail if the article text was available in English. Evidence synthesis The current literature exists as case reports or small case series, with no prospective or higher-order treatment studies available. Thus, an evidence-based approach to data synthesis was difficult. The available literature is presented objectively with an attempt to describe clinically relevant trends and findings in the diagnosis and management of DMI. Conclusions Early recognition of DMI is key, so appropriate treatment can be initiated. MRI is the radiological study of choice. A combination of bed rest, glycemic control, and non-steroidal anti-inflammatory drug therapy appears to yield the shortest time to symptom resolution and the lowest risk of recurrence.